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Introduction
Breast cancer is one of the most common malignancies worldwide, affecting millions of women annually in developed and developing communities. Its prevalence and increasing incidence has galvanized significant advances in the treatment options available, and continued advances in understanding of its biological underpinnings have revealed that breast cancer is both clinically and biologically heterogeneous. Considerable effort has been expended to identify tumor features that are prognostic of patient outcome, and/or predictive of responsiveness to particular treatment regimens. In this regard, a defining feature of breast cancers is the presence of estrogen receptor alpha (ERa), where ERa positive and ERa negative cancers are characterized by major differences in biology, sensitivity and response to treatment, and patient outcome. While ERa, progesterone receptor (PR) and epidermal growth factor receptor 2 (HER 2) are the histopathological markers that underpin current clinical management of breast cancer (Weigel and Dowsett, 2010) , the imperative for increasingly refined and personalized predictive tools has driven the inclusion of molecular profiling in breast cancer prognostication, and there is now a significant body of evidence that molecular profiling of transcripts expressed in breast cancer samples can contribute to classification of breast cancers and to prognostic signatures (Weigelt et al., 2010a) , now being tested in clinical trials (www.agendia.com/pages/mindact; Zujewski and Kamin, 2008) . Although molecular-based signatures have revealed a range of breast cancer subtypes with distinct responses to treatment and outcome, and can identify patients at higher risk of early recurrence, there are acknowledged limitations in the current signatures (Geyer et al., 2012) . These include the striking lack of overlap between signatures derived from different sample sets; their primary utility in ERa positive breast cancers and the lack of signatures that are predictive in both ERa positive and ERa negative cancers; the contribution of proliferation-related genes to signature performance (Venet et al., 2011) ; and the complicating influence of transcripts present in the variable proportion of normal tissue admixed with the cancer component of samples used in signature discovery (Weigelt et al., 2010b) . In addition, signatures based on the combined complement of genes expressed in cancer tissue at the time of sampling fail to provide insight into biological pathways or processes involved in carcinogenesis.
The emerging evidence for increased immune response activity as a predictor of improved prognosis has prompted a focus on signatures that incorporate immune pathways. These are proving to be useful in ERa negative breast cancers (Nagalla et al., 2013) , but identification of proliferationindependent signatures for ERa positive breast cancers, or signatures predictive in both ERa positive and ERa negative cancers, remains challenging. To overcome some of these limitations, and also to provide rational, pathway-based signatures of disrupted physiology in cancer tissues that may be relevant to prognosis, this study has directly quantitated changed gene expression between normal breast, and cancer tissue, as a basis for signature development. Our emphasis was two-fold: first, to base the discovery on accurately quantitated differences between normal and cancer tissue, and second, to focus on components of a gene family that serves as fundamental regulators of metazoan biology and are therefore active in every aspect of human physiology. The nuclear receptor (NR) superfamily of transcription factors are crucial in reproduction, development, growth, metabolism and homeostasis. In terms of pathophysiology, they play key roles in the cardiovascular and immune systems, the central nervous system and the musculoskeletal system, and in the genesis and progression of cancer (Conzen, 2008) . The NR family are expressed in the normal breast, and pan-repression of the majority of NR is associated with carcinogenesis (Muscat et al., 2013) , highlighting the rationale for a role for NR in development and progression of the disease.
The cell-and context-specificity of NR action occurs through their interaction with defined groups of coregulators, proteins that interact with NR to either activate or repress the transcription of specific genes (Lanz et al., 2007; McKenna and O'Malley, 2010) . The transcriptional outcome regulated by NR is dependent on the complement of coregulators present in the target cell. Using human breast specimens (pre-and post-menopausal normal breast, and ERa positive and ERa negative breast cancers), we have quantitated all known NR coregulators in the human breast, and identified NRcoregulator interactions altered in cancer. We have developed molecular signatures independent of proliferation that outperform existing discriminators, and of demonstrated utility in both ERa positive and ERa negative breast cancers.
Materials and Methods

2.1.
Human breast tissue cohorts and mRNA profiling by TaqMan low-density array (TLDA)
The breast tissue cohorts profiled in this study and the TLDA experimental procedures have been previously published (Muscat et al., 2013) . The present study employs the same experimental procedures to profile the expression of 238 coregulators (listed in Supplementary Figure 1) in the same human breast tissue cohorts. Briefly, we custom-designed micro-fluidic cards, TaqMan Low Density arrays from ABI (Applied BioSystems), which included 238 coregulators (as defined by the Nuclear Receptor Signaling Atlas (NURSA: www.nursa.org)) and 16 internal controls for normalization (these comprised 18S-Eukaryotic ribosomal RNA; ACTB e Actin, beta; 2M e Beta-2-microglobulin; GAPDH e Glyceraldehyde-3-phosphatedehydrogenase; GUSB e Glucuronidase, beta; HMBS e Hydroxymethylbilane synthase; HPRT1 e Hypoxanthine phosphoribosyltransferase 1; IPO8 e Importin 8; PGK1-Phosphoglycerate kinase 1; POLR2A e Polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa; PPIA e Peptidylprolyl isomerase A (cyclophilin A); RPLP0 e Ribosomal protein, large, P0; TBP e TATA box binding protein; TFRC e Transferrin receptor (p90, CD71); UBC e Ubiquitin C; YWHAZ e tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) against which to normalize the expression of the coregulators in normal and neoplastic breast tissue. These controls include 18S rRNA, GAPDH and RPLP0, validated real-time PCR controls in NURSA-supported nuclear receptor profiling studies (Holbeck et al., 2010) . The geNorm software embedded within the ABI/intergromics StatMiner V4.1 software package was used to compute least expression variation and select the most appropriate, stable and robust combination of internal control genes (MRPL19, PGK1, PPIA, TFRC and UBC) against which to normalise the expression data (against the median of the most stable controls).
For each sample, 1.5 mg of total RNA was reverse transcribed with random hexamers and SuperScript III reverse transcriptase (Invitrogen) in a total volume of 45 ml. A total of 100 ml reaction mixture containing 50 ml cDNA template (333 ng) in RNase-free water and an equal volume of TaqMan Ò universal master mix (Applied Biosystems, Foster City, CA) was added to each TLDA fill reservoir. Four reservoirs per sample were filled. The TLDA includes all coregulators and endogenous controls in triplicate. After sealing the plate, it was run on an ABI 7900HT Real Time instrument (Applied Biosystems).
We made use of the delta Ct (DCt) values previously obtained for the 48 NR in (Muscat et al., 2013) to perform combined analyses of the expression correlation pattern of nuclear receptors and coregulators in this study.
Normalization of TaqMan low density arrays
TLDAs were analyzed by the relative quantification method of DCt. The geNorm (Vandesompele et al., 2002) algorithm in the Integromics StatMiner software package was used to select the most stable house keeping genes to be used as reference for normalization. The Ct values (Supplementary Table 1 ) of each assayed genes were then normalized against the median of the selected house keeping genes to obtain the DCt values. Supplementary Figure 1 shows a boxplot of the DCt values of all coregulators in each of the 4 cohorts.
Filtering of outlier samples
Ct value measurements above 35 cycles were considered inaccurate. Samples for which more than 40% of genes had Ct values above 35 were deemed to be outliers and removed from subsequent analyses. Three samples (ERneg02TB003, ERneg08RMH456, ERpos07RMH188) were removed from both the nuclear receptor and coregulator TLDA data.
Principal Component Analysis
Principal component analysis of coregulator DCt values was performed in R with genes as variables to investigate the coregulators that best characterize the different patient cohorts. Three dimensional scatter plots of samples against the first 3 principal components were generated by the Scatterplot3d (Ligges and Machler, 2003) package.
Detection of differentially expressed genes
A moderated t-statistic test based on the limma framework implemented in the HTqPCR (Dvinge and Bertone, 2009 ) software package was used to detect differentially expressed genes. Genes having a Benjamini and Hochberg adjusted P-value less than 0.05 and at least 1.5 fold up or down-regulated were termed differentially expressed (Supplementary Table 2A ).
2.6.
Validation of combining NR and coregulator data by investigation of TLDA cross-card batch effect
As NR and coregulator data were derived from distinct TLDA cards, we determined the validity of a combined analysis of NR and coregulator data by comparing expression of the house keeping control genes on both the NR and coregulator TLDAs. In addition, unsupervised hierarchical clustering of samples based on raw Ct values of all NR and coregulator genes was performed to determine if samples clustered in a batch (array) specific manner. We found expression of the control genes to be highly consistent between arrays (r 2 value 0.98) with no evidence of cross-card batch effects in clustering of samples (results not shown).
Correlation-based analysis of nuclear receptors and coregulators interactions
Pairwise Spearman Rank Correlation coefficients were calculated for all possible pairs of nuclear receptors and coregulators in a cohort-specific manner. Two genes were considered highly correlated if the Spearman Rank Correlation coefficient was !0.7 or À0.7.
Pathways and functional analysis
Differentially expressed coregulators were separated into two groups based on the direction of change in expression (up-or down-regulated). The Ingenuity Pathways Analysis (IPA) Package was used to detect over-represented functional annotations and canonical pathways associated with up-regulated or down-regulated coregulators. Given the very small number of genes that were up-regulated, we assessed only enriched functional annotations for this group and retained annotations with enrichment P-value of less than 0.05. For downregulated coregulators, over-represented canonical pathways with Bonferroni adjusted P-values of less than 0.05 were retained.
2.9.
Breast cancer microarray datasets
In order to establish nuclear receptors and coregulators associated with prognosis, we compiled a large cohort of breast cancer gene expression microarrays with associated clinical data from previously published work. In total, we compiled 2227 breast cancer cases (of which 2189 were annotated with survival data) from multiple datasets profiled on the Affymetrix Hg133A platform and an additional 1992 breast cancer cases (of which 1853 were annotated with survival data) from the METABRIC study (Curtis et al., 2012) profiled on the Illumina HT-12 v3 platform. Supplementary Table 3 lists the microarrays datasets included in our analysis. fRMA (Frozen Robust Multiarray Analysis) normalization (McCall et al., 2010) was performed on the Affymetrix microarrays to enable combined analysis of the multiple datasets. This algorithm utilizes pre-computed estimates of probespecific effects and variances obtained from large publicly available databases. These pre-computed values are then used in concert with information from new array(s) for normalization and summarization, allowing separately processed datasets to be compared. fRMA normalized expression values were retrieved from inSilicoDb via its Bioconductor package. Illumina HT-12 v3 array data (EGAD00010000210 and EGAD00010000211) were downloaded from the European Genome Phenome Archive and the normalized expression values as published in the METABRIC publication were used.
To identify genes correlated with ERa expression, breast cancer microarrays profiled on Affymetrix Human HG133A arrays (listed in Supplementary Table 3) were divided into ERa positive and ERa e subsets based on the associated IHC ERa status. Pairwise Spearman Rank Correlation coefficients were calculated for each gene profiled on the array with each of the nuclear receptors: ESR1, REV-ERa Bb, GR, NOR1, LRH-1 and PR. Spearman Rank Correlation coefficient !0.7 or À0.7 were used to filter for genes showing high expression correlation with these nuclear receptors in either ERa positive or ERa negative breast cancers.
Identification of nuclear receptors and coregulators associated with prognosis
We employed the process outlined in Supplementary Figure 2 to identify nuclear receptors and coregulators, expression of which associates with patient survival. In this process, samples from each of the microarray platforms were randomly divided into two groups, one used for training and the other for validation. The Training and Validation sets were of comparable size, as was the ratio of patients with events to those without events. A bootstrap approach was employed to identify genes significantly associated with breast cancer survival in the Training Set. Specifically, we randomly sampled with replacement from the Training Sets and performed Univariate Cox Regression on the randomly selected subgroup. This process (sampling with replacement followed by Univariate Cox Regression) was repeated 1000 times. We then defined an r-index for each gene as the ratio of times out of the 1000 analyses that the gene showed significant association with survival (Adjusted Cox Regression P-value 0.05). We used distant metastasis free survival (DMFS) for samples where that information is available. For samples without associated DMFS information, the following survival measures in order of decreasing preference were used: relapse free survival (RFS), disease free survival (DFS) and disease specific survival (DSS).
For the Affymetrix Training samples, we identified 80 coregulators and 23 nuclear receptors with an r-index !0.75; 43 coregulators and 5 nuclear receptors were identified in the Illumina Training Set. Genes with an r-index of at least 0.75 on both Affymetrix and Illumina platforms were then selected for Multivariate Cox Regression adjusting for ERa status and node status. This process identified 3 nuclear receptors and 16 coregulators, expression of which significantly associates with patient survival independent of ERa status and node status on both microarray platforms (Supplementary Table 4 ).
Validation of NR and coregulator centered gene signature
Breast cancer microarray samples from the Validation Sets were used to assess whether the nuclear receptors and coregulators identified can predict patient survival. We assessed the performance of 3 gene signatures: (i) 19-gene signature (19 nuclear receptors and coregulators listed in Supplementary Table 4); (ii) 3-NR signature (PPARd, PGR and GR); and (iii) 3 NR plus cytoskeletal gene signature (PPARd, PGR, GR, CFL1 and GSN).
For each signature, samples from the Validation Sets were assigned risk scores calculated on the signed average of the signature genes expression (by the "sig.score" function from the genefu R package (Haibe-Kains et al., 2011) ). In this method, the sample risk score is calculated as the average of the weighted expression of the genes in each signature. We used the sign and magnitude of the Univariate Cox Regression coefficient of expression of each gene obtained from all samples of the Discovery Sets as the input coefficients into sig.score. Samples were then classified into 3 different risk groups based on the assigned risk scores: low (bottom tertile), intermediate (middle tertile) and high (top tertile). The performance of each gene signature was then assessed on Kaplan Meier and a Concordance Index [as detailed in (Harrell et al., 1996) ]. The Concordance Index represents the probability that, for a pair of randomly chosen comparable patients, the patient with the higher risk prediction will experience an event before the lower risk patient.
Further, using the Validation samples (Supplementary Figure 2) of METABRIC dataset, we tested the prognostic power of the 3NR, 3NRþcytoskeletal genes and the 19 genes in breast cancer subgroups identified by immunohistochemical marker staining. Subtype classification as assigned in the METABRIC dataset was used to categorize samples into subgroups (Normal-like, Basal, Luminal A, Luminal B, HERa 2). Then the risk prediction method as described above is used to test the prognostic power of the signatures in each of the subtypes. In this analysis, we estimated input coefficients into sig.score in a subtype specific manner instead of using all Discovery samples.
Prognostic performance of the NR and coregulator based signatures identified was assessed in comparison to 48 other published signatures (Venet et al., 2011 ) with the same sample cohorts and outcome association method detailed above.
Results
Expression of coregulators differs between normal and breast cancer tissues
Supervised hierarchical cluster analysis demonstrates that a majority of coregulators were expressed differently in breast cancers compared with normal breast and that the expression of many coregulators also differs between ERa positive and ERa negative cancers ( Figure 1A) . This observation is supported by unsupervised Principal Component Analysis (PCA), with normal and cancer samples clustering into two relatively well-defined subgroups reflecting the change in coregulator expression in cancer samples compared with normal tissue ( Figure 1B ). Expression levels of coregulators showed greater variation among cancer samples, evidenced by the greater spread observed on the PCA plot. In addition, expression profiles of coregulators also differ between ERa positive and ERa negative breast cancers. This difference is more evident when PCA was performed on the cancer samples independently of the normal samples ( Figure 1C) .
The changed expression of the majority of coregulators between normal and cancer cohorts supports the view that the separation of cohorts based on coregulator expression reflects multiple coregulator changes, each with an individually small contribution to the phenotype, rather than a few coregulators with a large effect on the phenotype. This is reflected in the small proportion of variance of each gene captured by each principal component in the PCA analysis (Supplementary Figure 3A) . The first principal component only accounted for w55% of the total variance in the dataset with each subsequent principal components capturing small increases in cumulative variance (Supplementary Figure 3B) .
Pan-repression of coregulators in neoplastic breast tissues
The majority of coregulators showed decreased expression in cancer compared with normal tissue, with coregulator repression more pronounced in ERa negative than ERa positive cancers ( Figures 1A and 2) .
Overall, ERa negative breast cancers are associated with more extensive disruptions in the coregulator transcriptome, Figure 2 e Differentially expressed coregulators Clustered heatmap of the log2 (Fold change) of significantly differentially expressed coregulators (adj. P-value £ 0.05 and at least 1.5 fold up or down regulated) illustrating that coregulator repression is more pronounced in ERa negative compared to ERa positive cancers. Panel A highlights a cluster of coregulators that are down regulated in both ERa positive and ERa negative breast cancers compared to normal breast. Panel B shows a cluster of coregulators with increased expression in either ERa positive or ERa negative cancers. Panel C highlights a subset of coregulators whose expression differs between ERa negative and ERa positive tumors.
with an increased number of genes differentially expressed plus an increase in the magnitude of the change in expression (Figure 2, Supplementary Table 2A) . Cluster A in Figure 2 highlights coregulators that are down-regulated in both ERa positive and ERa negative breast cancers compared with normal breast. Cluster B in Figure 2 shows coregulators with increased expression in either ERa positive or ERa negative cancers; cluster C in Figure 2 highlights coregulator expression that differs between ERa positive and ERa negative tumors.
Using a moderated t-test implemented in the HTqPCR package, we identified differentially expressed coregulators. On the criterion of at least 1.5 fold up or down-regulation and Benjamini Hochberg adjusted P-value 0.05, we found 101 (42%) of the 238 coregulators profiled in ERa positive cancer samples are differentially expressed compared with normal, of which 11 genes are up-regulated and 90 down- Table 2) .
Although a minority of coregulators are up-regulated in either ERa positive or ERa negative breast cancers compared with normal breast, most (10/12, 83%) of these are associated with Cellular Growth and Proliferation, and predicted to be activated, according to functional annotation on IPA (Fisher Exact P-value ¼ 1.03E-05, activation z-score ¼ 2.307, Supplementary Table 5A ). Of the up-regulated coregulators, only CNNE1 is specifically up-regulated in ERa negative breast cancers while CNNA2 and TRIP13 are up-regulated in both ERa positive and ERa negative cancers; the other 9 coregulators are upregulated specifically in ERa positive cancers ( Figure 2B , Supplementary Table 2B ).
In contrast with the specific association of coregulators up-regulated in breast cancer with NR pathways involved in proliferation and disease progression, coregulators that were down-regulated in either ERa positive or ERa negative breast cancers compared with normal were associated with a large range of NR pathways (Supplementary Table  5B ). Among the most significantly down-regulated pathways in breast cancer are Estrogen Receptor Signaling; RAR activation; Glucocorticoid Receptor Signaling, Aryl Hydrocarbon Receptor Signaling; TR-RXR Activation; and PPAR signaling. As noted above, the numbers of down-regulated pathways in cancer compared with normal was greater for ERa negative than for ERa positive breast cancers (Supplementary  Table 5B ).
3.3.
Relationships between expression of NR and coregulators in normal breast and breast cancer
To explore the potential functional parallels between NR and coregulators, we determined the correlation between NR and coregulator expression in each of the four breast cohorts (ERa positive, ERa negative, premenopausal normal, postmenopausal normal). This was done by combining the coregulator expression data of this study with previously published expression data for NR (Muscat et al., 2013) measured in the same cohort of samples. We first examined the pairwise expression correlation between each nuclear receptor and coregulator. Figure 3A shows the numbers of coregulators with expression highly correlated (Spearman Rank Correlation !0.7 or À0.7) with that of each nuclear receptor, with NR ranked by decreasing NR-coregulator associations in normal postmenopausal breast samples, where the most abundant NR-coregulator associations are observed. Transcript levels of NR such as RARg, RORg, VDR, RARb, HNF4g, RXRb, COUP-TF1/2, MR and PPARg are correlated with the largest number of coregulators in these tissues. Although fewer associations are evident in normal premenopausal samples, and in either ERa positive or ERa negative breast cancers, cancer-related gains and losses in NR-coregulator association are observed ( Figure 3A) . For example, expression of RARb correlates strongly with 97 coregulators specifically in postmenopausal normal but not in any of the other three sample cohorts. Likewise, expression of RXRa shows strong intercorrelation with multiple coregulators specifically in ERa positive cancer samples. In contrast, AR expression correlates with fewer coregulators and the correlation is only observed in ERa positive cancer samples. All nuclear receptors display positive correlation with coregulators except for PPARg, expression of which strongly and negatively correlates with more than 30 coregulators only in normal breast tissues (Supplementary Table 6) .
A major cancer-associated shift in the expression correlation patterns of nuclear receptors and coregulators is supported by Figure 3B , which illustrates the proportion of strongly correlated NR-coregulator pairs that are observed only in normal breast, ERa positive or ERa negative samples as well as those commonly observed in multiple cohorts. Only 36% of all highly correlated NR-coregulator pairs are common to both normal and cancer samples ( Figure The proportion of highly correlated NR-coregulator pairs in ERa negative cancer samples not observed in normal samples is much higher ( Figure 3B : ERa negative only, 26%) compared to that observed in ERa positive cancer samples ( Figure 3B : ERa positive only, 3%). This suggests that overall, ERa negative breast cancers are associated with increased dysregulation of the NRcoregulator interaction network compared with ERa positive cancers.
Several nuclear receptors displayed pan-ERa status changes in expression correlation with coregulators. Of particular interest are the nuclear receptors ERb, LXRa and PPARg which show either no or negative correlation with most coregulators in normal breast samples but strong positive correlation with coregulators in cancer ( Figure 3C ). Other nuclear receptors display ERa status-specific shifts in expression correlation with coregulators ( Figure 3D) . AR, ESRRg, RORg, RXRa and RXRg are highly correlated with multiple coregulators in ERa positive cancers and these correlations are disrupted in ERa negative cancers. In contrast, REV-ERBb, GR, NOR1, LRH-1 and PGR displayed the opposite pattern and acquire strong correlations with multiple coregulators specifically in ERa negative cancers. 3.4.
NR-coregulator interactions acquired in cancer have stronger prognostic power than NR-coregulator interactions disrupted between normal and cancer
To determine whether nuclear receptors that become strongly correlated with coregulators in ERa negative breast cancer ( Figure 3D 
ER-Cancers
Figure 4 e Prognostic value of NR displaying ERa -status specific expression correlations with coregulators. Kaplan Meier plots of the probability of survival for samples classified into Low, Intermediate and High risk groups based on the expression profile two different groups of nuclear receptors: Group 1 (Rev-erbb, GR, NOR1, LRH-1 and PR) and Group 2 (AR, ERRU, RORg, RXRa, RXRg). Samples from the Validation Sets (Supplementary Figure 2) were used for this analysis (927 samples profiled on Illumina HT12v3 arrays). Log rank Pval represent the log rank Pvalue for the Kaplan Meier curves. Cox.Reg.Pval is the univariate Cox Regression P-value for the association of sample risk scores with patient survival. C-index represents the Concordance Index calculated as detailed in Harrell et al. (1996) .
Breast cancer cases were classified into low, intermediate and high risk-groups based on risk scores calculated from the expression of the nuclear receptors in each of Panel 1 and Panel 2 in Figure 3D . Kaplan Meier plots of the probability of DMFS of the risk-groups for ERa positive and ERa negative breast cancers show that the expression of nuclear receptors displaying acquired correlations with multiple coregulators in ERa negative cancers (Group 1: Rev-ERBb, GR, NOR1, LRH-1 and PGR) significantly segregates patients at low from those at high risk (Figure 4) , and this is confirmed in an independent dataset (Supplementary Figure 4) . The expression of nuclear receptors showing disrupted interactions (Group 2: AR, ESRRg, RORg, RXRa and RXRg) has no predictive power for patient survival in ERa negative cancers while having modest predictive power in ERa positive cancers (Figure 4 and Supplementary Figure 4) .
Given that Group 1 (Rev-ERa Bb, GR, NOR1, LRH-1 and PGR) included NR linked with ERa expression and/or function, we asked whether the genes that acquired correlations with Group 1 NR in ERa negative cancers were ERa-associated, perhaps reflecting ERa-independent signaling in these cancers. Genes most strongly correlated with ERa were identified in the Affymetrix datasets (921 genes; Pearson correlation coefficient !0.7 or À0.7), and their correlation with the Group 1 NR determined. While GR and LRH-1 were correlated with few/no ERa-correlated genes in ERa positive cancers, they acquired such correlations in ERa negative cancers (Figure 5 ), supporting the possibility that these NR may be involved in ERa-associated but ERa-independent pathways. Although correlations were detected between PGR and these genes in ERa negative cancers, the significance level did not pass the cutoff threshold of 0.7 (not shown).
Prognostic value of nuclear receptors and coregulators in breast cancer
The prognostic power of the small number of nuclear receptors that acquired correlation with multiple coregulators in breast cancers (Figure 4 ) raised the question of whether coregulators, alone or in combination with nuclear receptors, were associated with breast cancer outcome. To address this question, we performed a comprehensive survey of the association of all nuclear receptor and coregulator expression levels with patient survival in large cohort of publicly available breast cancer microarray datasets. In total, we compiled gene expression data from over 4000 breast cancer tissue microarrays profiled on two microarray platforms: Affymetrix Hg133A (2189 samples) and Illumina HT-12 v3 (1853 samples) (Supplementary Table 3 ). Given the multiplicity of markers already linked to clinical outcome in breast cancer, and the challenges in identifying prognostic gene signatures that perform better than chance alone (Venet et al., 2011) , we employed the rigorous analytical approach outlined in Supplementary Figure 2 There were 3 nuclear receptors (GR, PGR, PPARd) and 16 coregulators with expression profiles robustly associated with patient survival, independent of ERa status or node status on both microarray platforms (listed in Supplementary Table  4 ). These genes have functional roles relevant to cancer biology including: cell cycle regulation (CDKN1C, CCNA2, CCNE1, PA2G4), cytoskeletal organisation (CLF1, GSN), chromatin modifiers (SMARCA2, HMGB2), known oncogenes or cancer-related genes (RPL7A, NSD1, PRAME, FUS), and also include 4 (33%) of the 12 genes that are increased in cancer compared with normal breast (Figure 2 : TRIP13, CCNE3, CCNA2, PRAME). Figure 6A Kaplan Meier analysis showed significant segregation of the three risk-groups ( Figures 6B and C) . Furthermore, classification of samples into low, intermediate and high risk-groups on expression profiles of just the 3 nuclear receptors (GR, PGR, PPARd) also results in significant segregation of low, intermediate and high-risk samples ( Figure 6D ). We also observed that addition of the two genes known to be involved in cytoskeletal organization (CFL1 and GSN) into the survival model together with the 3 NR resulted in further separation of the risk groups ( Figure 6E ).
We also tested the prognostic power of the 3NR, 3NRþcy-toskeletal genes and the 19-gene signature in breast cancer subgroups identified by immunohistochemical marker staining. The signatures had little or no predictive power in Basal and HERa 2 subtypes, but identified subgroups of patients with different prognosis in the Luminal A, Luminal B and Normal-like subtypes (not shown).
Performance comparison
A limitation of current breast cancer signatures is that most have been shown to be no more strongly associated with outcome than random sets of genes, although signatures containing over 100 genes are more significant (Venet et al., 2011) . We compared the performance of NR and coregulator centered gene signatures with 48 other published breast cancer signatures (compiled from Venet et al. (2011) ). Using samples from our Validation Sets, we calculated sample risk scores based on the expression of the genes in each signature. The association of the calculated risk scores with patient survival was then tested by Univariate Cox Regression and Concordance Index. Figure 7 shows the Concordance Index for each gene signature calculated for (i) all samples in the Validation Sets ( Figure 7A ) and (ii) ERa negative samples of the Validation Sets ( Figure 7B ). The 19-gene signature performance is comparable to signatures of larger sizes, in all cases ( Figure 7A ) and more particularly in ERa negative cases ( Figure 7B ). The signatures for the 5 NR that acquired correlations in ERa negative cancer (from Figure 4) ; and the 3 NR Plus Cytoskeletal gene signatures do not rank well when all samples of the Validation Sets are used ( Figure 7A ), they are, however, able to predict patient survival for ERa negative samples better than signatures with larger gene numbers ( Figure 7B ). We also observed that prediction accuracy of gene signatures varies, depending on the microarray platform used, with some signatures performing better on one microarray platform than the other. In ERa negative breast cancers, there are two published signatures that have comparable or fewer numbers of genes than the NR-coregulator signatures identified in this study, namely the Yu et al. (2007) (14 genes) and Buffa et al. (2010) (3 genes) signatures ( Figure 7B ). There was no overlap between the 19-gene NR-coregulator signature identified in this study, and the genes contained within either the Yu or Buffa signatures, nor did functional analysis reveal any overlap, with the Yu signature being associated with cell surface receptor linked signal transduction, immune response and cell motility (not shown).
It is known that most of the genes in breast cancer signatures are correlated with proliferation, and this is a major confounder in outcome prediction (Venet et al., 2011) . To assess the impact of proliferation on the prognostic power of the NR-coregulator gene signatures that we identified, we adjusted for the effect of proliferation by adjusting for the expression of the meta-PCNA signature, which comprises the genes most strongly correlated with Proliferating Cell Nuclear Antigen (PCNA) gene expression (Venet et al., 2011) . We found that while for ERa positive cancers, meta-PCNA adjustment reduced the prognostic power of most of the gene signatures we examined, it had minimal impact for ERa negative cancers and the 19-gene signature; the 5 NR that acquired correlations in cancer signature (from Figure 4) ; and the 3 NR plus cytoskeletal gene signature remained predictive of outcome in this cohort (Supplementary Figure 5) .
Discussion
This study comprises the first combined profiling of nuclear receptors and coregulators in the human breast. Notable strengths include the robust quantitation of coregulator transcripts in cohorts of curated human breast tissues, both normal and cancer, plus validation cohorts comprising of all publicly available breast cancer microarray datasets across all platforms. In this regard the study provides significant pathophysiologically relevant insights to supplement studies based on cell line models (Kittler et al., 2013) . Our findings reveal an almost pan-repression of coregulator expression in neoplastic breast tissue and show that ERa negative cancers are associated with more widespread disruptions of the coregulator transcriptome. In addition, the study highlights important cancer-associated shifts in nuclear receptor and coregulator expression patterns. We then complemented the expression profiling of nuclear receptors and coregulators with a comprehensive survey of the prognostic value of NR and coregulators in published breast cancer microarrays to identify nuclear receptors and coregulators with high prognostic significance. The coregulator transcriptome was strikingly disrupted in cancer compared with normal breast, with a small number of coregulators up-regulated and the majority repressed. Upregulation was overwhelmingly associated with proliferation, HT12v3 arrays. D) and E) Kaplan Meier plot showing significant segregation of 1094 validation samples profiled on Affymetrix Hg133a arrays classified into Low and High risk-groups based on the expression of (D) the 3 nuclear receptors GR, PGR and PPARd; and (E) the 3 nuclear receptors and two cytoskeletal genes CFL1 and GSN. consistent with different regulatory networks being operative in both ERa positive and ERa negative breast cancers; differential expression of the two cyclins CCND1 and CCNE1 in ERa positive and ERa negative cancers suggest different mechanisms for controlling progression of G1 to S phase of the cell cycle in these two subgroups. CCND1 is upregulated in ERa positive and down-regulated in ERa negative cancers, consistent with published reports that ERa can induce CCND1 expression (Cicatiello et al., 2010) . It is possible that in ERa negative cancers progression from G1 to S phase is mediated through CCNE1, which is specifically upregulated in ERa negative cancers in contrast with the decreased level of CCND1. In addition, the coregulators VAV3, a Rho GTPase guanine nucleotide exchange factor, and SPDEF, the SAM pointed domain containing ETS transcription factor, are up-regulated specifically in ERa positive breast cancers and down-regulated in ERa negative breast cancers, consistent with previously published reports that VAV3 overexpression enhances ERa-mediated signaling (Doolan et al., 2008) , and that SPDEF is associated with patient survival in ERa positive breast cancers (Sood et al., 2009 ). Up-regulation of both RARa and CRABP2 (cellular (90) ABBA (111) SAAL (162) VANTVEER (60) HALLSTROM (78) SOTIRIOU-93 (343) IVSHINA (17) WHITFIELD (587) META-PCNA (129) CARTER (70) MA (30) 19-genes (19) YU (14) PAWITAN (46) SHIPITSIN (56) CHANG (355) BEN-PORATH-EXP1 (367) DAI (35) RHODES (67) LIU (167) PAIK (16) TAUBE (242) KOK (179) RAMASWAMY (16) GLINSKY (11) WEST (468) REUTER (714) WONG-MITOCHON (217) WANG-76 (69) WONG-PROTEAS (46) HUA (1345) BUFFA (3) CHI (136) KORKOLA (21) MORI (156) MILLER (18) 3NRs_plus_Cytoskeletal (5) ADORNO (2) BEN-PORATH-PRC2 (631) WANG-ALK5T204D (239) HE (6) 3NRs (3) HU (13) BUESS ( retinoic binding protein 2) specifically in ERa positive cancers is further evidence for differential regulation, in the case of retinoic acid signaling, in ERa positive and ERa negative breast cancer subgroups. Pan-repression of coregulator expression in neoplastic breast tissues was not unexpected given our earlier observation that breast cancer is associated with a pan-repression of nuclear receptors except for EAR2, AR, RARa and the NR4A subgroup (Muscat et al., 2013) . The specific mechanisms whereby repression of nuclear receptors and coregulators is involved in breast cancer pathogenesis are unclear. In cancers multiple NR-mediated pathways associated with cell differentiation were repressed, eg Retinoic Acid Activation and Glucocorticoid Receptor Signaling pathways; with up-regulation of cell cycle related genes this would have a net effect of increased cell growth and proliferation.
In the absence of detailed genomic localization maps and proteineprotein interaction data for most nuclear receptors and coregulators in breast cancer tissues, and the impossibility of experimentally deriving functional data from human tissue cohorts, we determined the correlation between NR and coregulator expression as a measure of functional relatedness. While setting very strong correlation thresholds for significance, we acknowledge that correlated expression indicates, but does not prove, functional co-operation. Nevertheless, this approach has revealed interesting insights into the complex regulatory networks of nuclear receptors in the human breast.
First, most of the strong NR-coregulator correlations occurred in the normal postmenopausal breast, with NR including RARg, RORg, VDR, RARb, HNF4g, RXRb, COUP-TF1/ 2, MR and PPARg associating with the largest number of coregulators, and pointing to the potential for active signaling networks around these receptors in normal breast. These NR were also associated with coregulators in pre-menopausal breast, but less frequently. Many if not all of these associations were lost in cancer, consistent with the overall down-regulation both of NR (Muscat et al., 2013) and coregulators (this study) in cancer compared with normal tissue. NR that acquired expression correlations (Rev-ERBb, GR, NOR1, LRH-1, PR) specifically in ERa negative breast cancers predicted poorer outcome for those patients, suggesting the potential for clinically significant activation of new signaling networks associated with unrestrained cancer biology involving these NR specifically in ERa negative breast cancers. Interestingly, NR whose associations with coregulators are disrupted in ERa negative breast cancers are not as strongly associated with patient outcome. This finding is particularly interesting in the context of regulatory networks, given that cancer is not simply a disease with a genetic basis but is ultimately driven by perturbations at the network level (Creixell et al., 2012) . During cancer development, it is likely that signaling processes are not simply disrupted but are also re-wired resulting in new signaling landscapes favorable to the development of the cancer cells. It is therefore perhaps logical that those re-wired signaling processes favoring maintenance and progression of cancer will have a stronger impact on patient outcome.
Secondly, we observed a positive correlation between the expression of most nuclear receptors and coregulators, with the exception of PPARg, ERb and RXRg, expression of which inversely correlates with multiple coregulators specifically in normal but not cancer tissues. It is arguably more logical for the expression of nuclear receptors to be positively correlated with that of coregulators for co-operational control of gene regulation. It is more unexpected to observe patterns of widespread inverse correlations, as in the case of PPARg; PPARg and its coregulator PPARgC1A are both strongly downregulated in both ERa positive and ERa negative cancers, consistent with reports that the presence of PPARg is associated with an anti-tumorigenic effect (Bonofiglio et al., 2006; Lu et al., 2005; Suzuki et al., 2006) . PPARg positively correlates with very few genes, among which are the tumor suppressor CAV1, the testosterone 17-beta-dehydrogenase gene HSD17B13 and the aldo-keto reductase AKR1C1/AKR1C2 gene. HSD17B13 is involved in estrogen biosynthesis and responsible for converting estrone to estradiol-17-beta while AKR1C1/AKR1C2 catalyses the reduction of progesterone to the inactive 20a-hydroxy-progesterone. Both HSD17B13 and AKR1C1/AKR1C2 are strongly down-regulated, consistent with attenuated steroid metabolism, in both ERa positive and ERa negative cancer samples. The strong positive correlation of PPARg with HSD17B13 and AKR1C1/AKR1C2 in normal breast only, its repression in cancer and the striking inverse correlation pattern between PPARg and multiple coregulators suggest that dysregulation of this NR might contribute to altered steroid metabolism and thereby to aberrant control of estrogen and progesterone mediated signaling in breast cancer.
The demonstration that NR-coregulator associations in normal breast are disrupted in cancer, and the acquisition of associations unique to cancer tissues, signal the potential for NR-coregulator networks not only to be implicated in the biology of breast cancer but also relevant to clinical outcome. Testing of such possibilities, in order to discover meaningful associations between gene signatures and clinical outcome, is fraught with pitfalls in that most current breast cancer signatures are not robust across datasets and microarray platforms, and moreover are no more strongly associated with outcome than random sets of genes (Venet et al., 2011) . This is probably due to the extremely high individual variability of sampled tumor expression profiles resulting in passenger signals overwhelming the real cancer signature. To circumvent this limitation, we employed a bootstrap resampling approach on 2 different microarray platforms. There were only 19 genes (3 nuclear receptors (GR, PGR, PPARd) and 16 coregulators) with expression profiles robustly associated with patient survival, independent of ERa or node status on both microarray platforms. Low levels of expression of the signature genes identify patients with a significantly lower probability of distant metastases, across both the microarray platforms, whereas high expression is associated with poorer prognosis. Low expression of the 3 NR alone, or of the 3 NR with the cytoskeletal genes, also stratified patients with better prognosis. Two of the 3 NR in the 19-gene signature (GR, PPARd) have been identified by ChIP-chip to be central nodes in a regulatory network of NR and associated transcription factors in MCF-7 cells (Kittler et al., 2013) , and their robust association with clinical outcome identified in this study highlights the importance of signaling networks specifically associated with these 3 NR in breast cancer.
To evaluate how well NR-coregulator-based signatures performed in comparison to other published breast cancer signatures, and mindful of the weak predictive power of published signatures containing fewer than 100 genes, the performance of the NR-coregulator-based signatures was compared to that of all published breast cancer signatures. The performance of the 19-gene NR-coregulator-based signature is comparable to many other signatures of much larger sizes in predicting outcome for all breast cancer samples (both ERa positive and ERa negative), highlighting the power of predictive signatures derived from the quantitative determination of altered gene expression between normal breast and breast cancers.
This study highlights major differences in coregulator expression and NR-coregulator interaction between ERa positive and ERa negative breast cancers that reflects divergent regulatory controls in these two breast cancer subtypes. Specifically, a majority of the profiled coregulators (81%) are differentially expressed between ERa positive and ERa negative breast cancers, with ERa negative cancers being associated with an increase in both the number of coregulators being repressed as well as an increase in the magnitude of the repression. The change in coregulator expression is associated with ERa-specific perturbations in NR-coregulator expression. Specifically, RXRa, TRa, COUP-TF2, RORg showed strong associations of with multiple coregulators in ERa positive breast cancers suggesting the increased importance of retinoic acid signaling in this subtype and consistent with proliferation being a major influence on patient outcome in ERa positive cancers. ERa negative cancers, on the other hand, are associated with acquired interactions between REVERBb, TR4, GR, PPARa, NOR1, LRH-1 and a large number of coregulators. NR-coregulator interactions acquired specifically in ERa negative cancers have the potential to impact a wide range of cellular pathways and processes including chromatin remodeling, glucocorticoid receptor signaling and cell cycle regulation. Overall, our results suggest that ERa negative breast cancer is associated with increased severity in perturbation of normal NR-coregulator interactions and that there exists significant differences in the way normal gene regulatory networks are altered in these breast cancers. As a consequence, some NR and coregulators have stronger influence on patient outcome in ERa negative or positive breast cancer compared to the other. We observed that the 3NR plus cytoskeletal genes obtained the highest Concordance Index for ERa negative cancer, with its performance in predicting outcome for ERa positive cancer less robust. In addition, PCNA-adjustment has minimal influence on the prognostic power of most gene signatures in ERa negative cancers. It is thus possible that while proliferation is a major influence on outcome association in ERa positive cancers, it is not the principal factor that influences outcome for ERa negative breast cancers. ERa negative breast cancer outcomes might be driven by factors including cell movement and metastasis, as suggested by the strong influence of cytoskeletal genes in predicting patient outcome for this subgroup. In addition, we demonstrated that NR showing acquired correlations with multiple coregulators specifically in ERa negative cancers have stronger influence on patient outcome in these cancers. This observation emphasizes the importance of examining not only "loss-of-function" disruptions but also "gain-of-function" perturbations in the search for therapeutic and prognostic markers for breast cancer.
In conclusion, this study has identified networks of nuclear receptor-coregulator interactions active in normal breast but disrupted in breast cancer, and moreover provides evidence that signatures based on NR networks disrupted in cancer can provide important prognostic information in breast cancer patients, including ERa negative patients, for whom existing prognostic measures are limited.
